HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Hand-out
Press Releases
Soligenix, Inc.  
January 14, 2025

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Study Supported by $2.6 Million FDA Orphan Products Development Grant

avatar profile Olean Times Herald

Olean Times Herald


Local & Social